Jaguar Health files two Form D notices for equity offerings totaling $42.8 million

Jaguar Health, Inc., a Delaware-incorporated pharmaceutical company based in San Francisco, filed two Form D notices with the Securities and Exchange Commission dated June 30, 2026, disclosing separate exempt securities offerings.

In the first filing, the company reported a total offering amount of $40,800,000, with the total amount sold also at $40,800,000 and nothing remaining to be sold¹. The notice listed a single investor who had already invested in the offering¹.

The second filing covered a smaller raise, with a total offering amount of $2,000,000, fully sold, leaving nothing remaining to be sold². That offering had two investors who had already invested².

Both notices listed a date of first sale of June 9, 2026^1,2, and both were filed under the same exemption, with Rule 506(b)^1,2 selected. Neither filing was made in connection with a merger, acquisition, or exchange offer, according to the company's response to the business combination question in both notices.

The related persons listed across both filings included Lisa Conte as an executive officer and director, along with executives Carol Lizak, Steven King, Jonathan Wolin, and Pravin Chaturvedi, and directors James Bochnowski, John Micek III, Anula Jayasuriya, and Jonathan Siegel, as shown in the issuer's related persons disclosures. Both notices were signed by Lisa A. Conte, President and CEO^1,2.

Neither filing reported any sales commissions or finders' fees, and both indicated no proceeds were designated for payments to the named executive officers, directors, or promoters.